Pith. sign in

REVIEW 6 cited by

The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2404.15009 v4 pith:OOCGJ3QE submitted 2024-04-23 cs.CV eess.IV

The Brain Tumor Segmentation in Pediatrics (BraTS-PEDs) Challenge: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)

classification cs.CV eess.IV
keywords brats-pedsbraincbtn-connect-dipgr-asnr-miccaichallengechildrenclinicalpediatrictrials
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge, focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 6 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. Energy-based Tissue Manifolds for Longitudinal Multiparametric MRI Analysis

    cs.CV 2026-04 unverdicted novelty 7.0

    A patient-specific energy manifold learned from baseline multiparametric MRI provides a geometric reference system for tracking longitudinal tissue changes through energy and displacement analysis in sequence space.

  2. Energy-based Tissue Manifolds for Longitudinal Multiparametric MRI Analysis

    cs.CV 2026-04 unverdicted novelty 7.0

    Patient-specific energy manifolds from baseline mpMRI scans act as fixed geometric references to monitor longitudinal evolution of voxel distributions in sequence space for neuro-oncology proof-of-concept cases.

  3. BiSegMamba: Efficient Bidirectional Tri-Oriented Mamba for 3D Medical Image Segmentation

    cs.CV 2026-05 unverdicted novelty 6.0

    BiSegMamba is a bidirectional tri-oriented Mamba architecture that improves performance and reduces FLOPs in 3D medical image segmentation across brain, cardiac, abdominal, and vascular tasks.

  4. Energy-based Tissue Manifolds for Longitudinal Multiparametric MRI Analysis

    cs.CV 2026-04 conditional novelty 6.0

    A baseline-trained energy manifold in MRI intensity space showed progressive drift toward the tumour regime in a recurrence case but not in a stable case, suggesting a segmentation-free longitudinal monitoring signal.

  5. Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-Guided Subtyping and Lesion-Wise Model Ensemble

    cs.CV 2025-12 unverdicted novelty 4.0

    A radiomic-guided subtyping and lesion-wise ensemble pipeline delivers segmentation performance comparable to top entries on diverse BraTS 2025 brain tumor datasets.

  6. Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-Guided Subtyping and Lesion-Wise Model Ensemble

    cs.CV 2025-12 conditional novelty 4.0

    A radiomic-guided, lesion-aware ensemble with per-cluster post-processing yields strong segmentation across pediatric, meningioma, and metastasis MRI cohorts, though 'top-ranked' parity is asserted rather than shown.